An experimental treatment has demonstrated the potential to delay Alzheimer’s symptoms in individuals genetically predisposed to developing the disease in their 40s or 50s. According to recent findings published in The Lancet Neurology, long-term use of amyloid-removing drugs has shown positive results. Researchers at Washington University in St. Louis carried out a study that observed 22 participants who had undergone the treatment for an average period of eight years. Data revealed that this extended amyloid removal reduced the risk of symptom onset by half. The research targets families with rare gene mutations that nearly guarantee Alzheimer’s development, providing valuable insights into the treatment’s effectiveness. Participants have now transitioned from the initial experimental drug to Leqembi, a U.S.-approved IV treatment, to assess its long-term impact.

Funding challenges have emerged as a significant concern for the continuation of this research. The study’s lead investigator, Dr. Randall Bateman, stated that funding delays from the National Institutes of Health (NIH) threaten to halt the project. These delays coincide with political uncertainties following the nomination of Dr. Jay Bhattacharya as NIH director. Bhattacharya previously suggested that Alzheimer’s research should explore broader scientific approaches rather than focusing heavily on amyloid-related treatments. Despite the debate, researchers emphasize that amyloid buildup remains a key factor in Alzheimer’s progression. Ongoing studies now include investigations into tau proteins, inflammation, and immune responses in the brain. Without stable funding, scientists warn that vital opportunities to delay or prevent Alzheimer’s symptoms may be lost.